Sign in Register

Zejula (niraparib tosylate)

Advertisement

Last reviewed · Source: First Databank (FDB) drug data

Overview

USES: Niraparib is used to treat ovarian cancer, fallopian tube cancer, or a type of cancer of the abdomen (primary peritoneal cancer). It works by slowing the growth of cancer cells.

Generic name: niraparib tosylate
Pronunciation: (nye-RAP-a-rib)

Reference product & biosimilars

No reference, biosimilar or interchangeable associated with this drug.

Today’s intelligence on Zejula

Intelligence content is not available yet.

Indications

The following indications are listed for Zejula:

  • Epithelial Ovarian Cancer With Brca Mutation
  • Homologous Recombination Deficiency (Hrd)-Positive Ovarian Cancer

Also known as: Brca Mutation-Associated Ovarian Cancer, Malignant Neoplasm Of Ovary Associated With Germline And/Or Somatic Brca Mutation, Ovarian Cancer With Germline And/Or Somatic Brca Mutation.

Dosing

No dosing information is available for this tab.

Drug interactions

There is no enhanced messaging for this drug.

Contraindications

There is no enhanced messaging for this drug.

Adverse reactions

There is no enhanced messaging for this drug.

Precautions

No enhanced messaging available.

ICD codes

No ICD codes are available for this drug.

Formulary status

Search health-plan coverage for this drug by ZIP code.

Enter a 5-digit ZIP code. Searching does not change your profile.

Enter a ZIP code to view available health plans.

Last reviewed · Source: First Databank (FDB) drug data